Loading...
Loading...
DCTH| Name | Value |
|---|---|
| Revenues | 7.8M |
| Cost of Revenue | 1.5M |
| Gross Profit | 6.2M |
| Operating Expense | 10.2M |
| Operating I/L | -3.9M |
| Other Income/Expense | -9.8M |
| Interest Income | 0.0M |
| Pretax | -13.7M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -13.7M |
Delcath Systems, Inc. is an interventional oncology company specializing in the treatment of primary and metastatic liver cancers. Its primary revenue-generating product is the HEPZATO KIT, a hepatic delivery system for administering high-dose chemotherapy directly to the liver, minimizing systemic exposure and associated side effects. The company's FOCUS clinical trial aims to investigate the objective response rate in metastatic ocular melanoma. Additionally, Delcath Systems offers the CHEMOSAT Hepatic Delivery System for Melphalan as a stand-alone medical device for sale in Europe, catering to medical centers treating various liver cancers.
